FREA Stock Chart & Stats
€10.30
-€0.20(-1.90%)
At close: 4:00 PM EDT
€10.30
-€0.20(-1.90%)
Day’s Range― - ―
52-Week Range€8.60 - €20.00
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€25.11B
Enterprise Value€38.13K
Total Cash (Recent Filing)€1.28B
Total Debt (Recent Filing)€11.41B
Price to Earnings (P/E)16.4
Beta0.96
Next Earnings
Nov 04, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding2,252,949,200
10 Day Avg. Volume9
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)5.76
Price to Sales (P/S)5.00
P/FCF Ratio95.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.91
Revenue Forecast (FY)€23.65B
Bulls Say, Bears Say
Bulls Say
Revenue And Margin RecoverySustained TTM revenue growth with expanding net margins indicates the group is exiting its prior loss cycle and restoring earnings power. Durable margin recovery across segments supports reinvestment, debt reduction and operational resilience, improving medium‑term earnings predictability.
Improved Cash Generation & LeverageMaterial free cash flow and net debt/EBITDA inside the 2.5–3x target underpin balance sheet optionality. Durable cash generation supports capex for growth, bond financing access and disciplined capital allocation, reducing refinancing risk and enabling strategic investments.
Biopharma Market Share & Regulatory WinsStrong organic growth and meaningful biosimilar market share gains demonstrate commercial competitiveness and pricing traction. Regulatory approvals expand addressable markets and lower execution risk, supporting sustainable revenue and margin contribution from higher‑value biopharma products.
Bears Say
Volatile Cash Conversion & Historical LossesInconsistent cash conversion reduces the reliability of internally generated funds to support growth or distributions. Recurring volatility and past net losses mean the company may need external financing in weaker periods, constraining strategic flexibility and increasing sensitivity to macro shocks.
Regulatory / Manufacturing Risk (FDA OAI)An OAI carries remediation obligations that can raise compliance costs and create production uncertainty. Persistent manufacturing regulatory issues can limit supply, disrupt customer relationships and require capital or operational changes, posing a structural execution risk for product continuity.
China Nutrition Tendering & VBP HeadwindsSustained volume‑based procurement and tendering in China politically compress pricing and margins in a large growth market. Structural tender dynamics can reduce revenue per-unit and force product portfolio shifts, limiting long‑term growth and margin sustainability in the region.
Fresenius SE & Co News
FREA FAQ
What was Fresenius SE & Co’s price range in the past 12 months?
Fresenius SE & Co lowest stock price was €8.60 and its highest was €20.00 in the past 12 months.
What is Fresenius SE & Co’s market cap?
Fresenius SE & Co’s market cap is €25.11B.
When is Fresenius SE & Co’s upcoming earnings report date?
Fresenius SE & Co’s upcoming earnings report date is Nov 04, 2026 which is in 52 days.
How were Fresenius SE & Co’s earnings last quarter?
Fresenius SE & Co released its earnings results on Aug 04, 2026. The company reported €0.206 earnings per share for the quarter, missing the consensus estimate of €0.214 by -€0.008.
Is Fresenius SE & Co overvalued?
According to Wall Street analysts Fresenius SE & Co’s price is currently Overvalued.
Does Fresenius SE & Co pay dividends?
Fresenius SE & Co does not currently pay dividends.
What is Fresenius SE & Co’s EPS estimate?
Fresenius SE & Co’s EPS estimate is 0.19.
How many shares outstanding does Fresenius SE & Co have?
Fresenius SE & Co has 2,252,949,200 shares outstanding.
What happened to Fresenius SE & Co’s price movement after its last earnings report?
Fresenius SE & Co reported an EPS of €0.206 in its last earnings report, missing expectations of €0.214. Following the earnings report the stock price went down -7.759%.
Which hedge fund is a major shareholder of Fresenius SE & Co?
Currently, no hedge funds are holding shares in DE:FREA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.30%
12-Months-Change
Fundamentals
Return on Equity
2.36%
Trailing 12-Months
Asset Growth
-1.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fresenius SE & Co
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.
FREA Company Deck
FREA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was decisively positive: management reported broad‑based operational momentum across Kabi, biopharma, MedTech and Helios, delivered strong Q2 results (core EPS +14% CER, EBIT +10% CER), expanded margins and ROIC, strengthened cash generation and raised full‑year core EPS guidance to 10%–15%. Noted risks — an OAI at a U.S. manufacturing site, isolated manufacturing adjustments, China VBP headwinds, regional softness in parts of Helios and external input‑cost pressures — are acknowledged and being managed, but they do not materially detract from the upbeat operational and financial story presented.View all DE:FREA earnings summariesTechnical Analysis
Option Care Health
―
DaVita
―
Fresenius Medical Care
―
HCA Healthcare
―
Tenet Healthcare
―